Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Ann Neurol. 2018 Apr 27;83(5):980–993. doi: 10.1002/ana.25235

Table 3.

Baseline demographics and clinical characteristics of all enrolled subjects (comparing those with and without asymptomatic intracranial hemorrhage at or before the 24 h unenhanced head CT. The one subject with symptomatic ICH was excluded from this analysis.

No ICH at 24 h (n=58) Asymptomatic ICH at 24 h (n=21) p value
Age (±SD) 68±13 66±15 0.56
Male (%) 33 (56.9%) 9 (42.9%) 0.31
Race White (%) 36 (62.1%) 11 (52.4%) 0.45
Lacunar Subtype (vs. non-lacunar)* 21 (36.8%) 0 (0%) <0.001
Pre-stroke mRS 0–1 49 (84.5%) 19 (90.5%) 0.72
Medical History (%)
 Atrial Fibrillation 9 (15.5%) 12 (57.1%) <0.001
Initial NIHSS 5.5 (4–10) 16 (10–19) <0.001
Blood Glucose, mg/dL 119.5 (102–180) 118 (104–160) 0.65
Systolic Blood Pressure, mm Hg 158 (143–171) 150 (148–171) 0.66
Diastolic Blood Pressure, mm Hg 82.5 (72–89) 84 (73–93) 0.49
Initial INR 1.00 (0.90–1.07) 1.08 (1.00–1.10) 0.04
FLAIR Signal Intensity Ratio 1.08 (1.02–1.11) 1.10 (1.03–1.13) 0.08
FLAIR Negative (%) 28 (48.3%) 12 (57.1%) 0.61
Total alteplase dose, mg 72.7±14.1 75.9±14.4 0.37
Symptom Discovery to thrombolysis, h 3.62 (3.02–4.03) 3.00 (2.83–3.75) 0.02
Last Known Well to thrombolysis, h 11.62 (10.23–13.42) 10.53 (7.93–12.67) 0.13
Arrival-to-thrombolysis, h§ 1.78 (1.40–2.23) 1.76 (1.43–2.30) 0.98
Arrival-to-MRI, h§ 0.89 (0.58–1.28) 0.73 (0.57–1.06) 0.55
MRI-to-thrombolysis, h 0.86 (0.62–1.02) 0.90 (0.73–1.07) 0.41
Stroke upon awakening 44 (75.9%) 12 (57.1%) 0.16

Data are mean±SD, n (%), or median (IQR). ICH, intracranial hemorrhage, INR, international normalized ratio.

*

The stroke mimic who had no ICH was excluded since no stroke subtype.

Subjects were assumed to not have the condition unless explicitly documented in their medical record.

**

Current smokers are compared to everyone else, including past smokers, never smokers, and unknown status.

Two subjects were missing initial INR in the no-ICH group.

§

Excluding one subject with symptom discovery after arrival.